Editorial: Bridging Molecular Targets and Neural Circuits in Psychiatric Therapeutics

Weijie Xie ^1* Yuan Li ² Song Zhang ³

• ¹ Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, China
• ² Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai, Shanghai Municipality, China
• ³ Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Neuroinflammation and oxidative stress are pivotal contributors to neurodegenerative and psychiatric disorders. Two studies exemplify how novel compounds can mitigate these processes. Xixi Hou et al. synthesized 2H-1,4-benzoxazin-3(4H)-one derivatives fused with 1,2,3-triazole, demonstrating potent anti-inflammatory effects in LPSstimulated microglia. These compounds suppressed pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and activated the Nrf2-HO-1 pathway, underscoring their dual antioxidant and anti-inflammatory potential. Similarly, Chencen Lai et al. revealed that (+)-catechin alleviates corticosterone-induced oxidative stress and pyroptosis in PC12 cells by activating PI3K/AKT and Nrf2/HO-1/NF-κB pathways. Both studies emphasize the therapeutic promise of targeting oxidative-inflammatory cascades, particularly through Nrf2 activation, to preserve neuronal integrity.Cutting-edge neuroimaging techniques continue to unravel how neuromodulators and disease states reshape brain networks. Abraham Tonny Hagan et al. demonstrated that intranasal oxytocin enhances small-world topology in resting-state networks, particularly in regions governing social cognition. This suggests oxytocin's therapeutic potential lies in optimizing information flow within critical circuits.Complementing this, Ye Liu et al. employed bibliometric analysis to identify adult hippocampal neurogenesis (AHN) as a hotspot, linking its dysfunction to Alzheimer's disease and anxiety. Meanwhile, Xin Che et al. used ¹ H-MRS to correlate hippocampal metabolite ratios with cognitive decline in general paresis patients, highlighting neuroimaging's role in tracking neurodegeneration. Together, these studies illustrate how multimodal imaging and meta-analyses can bridge molecular changes to brain neurocircuit-level dysfunctions.The efficacy and side effects of psychotropic drugs remain central to clinical psychiatry. Kuan Zhao et al. compared five antidepressants in cancer patients, revealing escitalopram, duloxetine, and vortioxetine as superior to sertraline, with trazodone augmentation enhancing outcomes. However, metabolic side effects of antipsychotics, such as olanzapine-induced weight gain, pose significant challenges.Lixuan Huang et al. identified lipid metabolism dysregulation in the lateral septum as a key driver of olanzapine's adverse effects, implicating APOA1/APOC3/APOH genes. Conversely, Ke Zhang et al. demonstrated that the α2-adrenoceptor agonist dexmedetomidine alleviates pain by restoring neuronal metabolism and spinal perfusion, suggesting metabolic modulation as a dual therapeutic strategy. These findings underscore the need for precision medicine to balance efficacy and safety. Mitochondrial dysfunction is a common thread in brain injury and neurodegeneration.Ting Zhu et al. demonstrated that Dl-3-n-butylphthalide (NBP) mitigates cerebral ischemia/reperfusion injury by enhancing mitochondrial fusion via AMPK/Mfn1 activation. This aligns with broader efforts to harness mitochondrial dynamics as a neuroprotective strategy, providing hope for stroke and related disorders.This Research Topic underscores the complexity of mental disorders and the need for interdisciplinary approaches, including multi-target therapies (e.g., Nrf2 activators, PI3K/AKT enhancers), precision neuroimaging, genetic and omics-driven insights, and mitigating drug side effects. Future research should prioritize translational studies bridging preclinical findings to clinical trials, leveraging emerging technologies like single-cell omics and AI-driven drug discovery. By integrating these avenues, we advance our understanding and ability to manipulate the neural circuits related to mental health, ultimately aiming to apply these advancements in clinical settings.